(RTTNews) - Biogen Inc. (BIIB) expects its fourth-quarter 2025 results to include approximately $222 million in acquired in-process research and development (IPR&D), upfront, and milestone expenses on a pre-tax basis, the company said in an SEC filing. The charge is expected to reduce earnings per share by about $1.26.
The expenses relate to collaboration and licensing agreements, including upfront and milestone payments, as well as premiums on equity securities and asset acquisitions of acquired in-process R&D.
On Tuesday, Biogen shares closed at $178.30, down 3.95%.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
